Leukemia/Lymphoma
RSSArticles
-
Prednisone Myeloma Remission Maintenance
-
Radiosurgical Boost for Primary High-Grade Gliomas
-
Microinvasion — When is it Invasive?
-
Honing in on BRCA Genetic Testing
-
Problems with HER2 Testing
-
Cancer Screening for Primary Care Physicians: Part II
-
Clinical Briefs in Primary Care Supplement
-
Sleep is not the answer to fighting cancer fatigue
-
Promising Long-Term Results of Imatinib for CML
Imatinib inhibits the BCR/ABL tyrosine kinase in CML, leading to improved responses over standard therapy. This report provides 5 year follow-up from the seminal IRIS study of upfront imatinib for chronic phase CML among the 553 patients randomized to 400 mg of imatinib. -
Trastuzumab in The Adjuvant Treatment of Breast Cancer: New Evidence from The HERA Study
Trastuzumab has previously been demonstrated to be active against HER2 positive breast cancer when used in the metastatic setting.